# Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia

> **NCT01588522** · PHASE1 · COMPLETED · sponsor: **BPGbio** · enrollment: 28 (actual)

## Conditions studied

- Chemotherapy-Induced Alopecia

## Interventions

- **DRUG:** Compound 31543 Calcitriol 5 μg/mL
- **DRUG:** Compound 31543 Calcitriol 10 μg/mL
- **DRUG:** Compound 31543 Calcitriol 20 μg/mL
- **DRUG:** Compound 31543 Calcitriol 40 μg/mL
- **DRUG:** Compound 31543 Calcitriol 60 ug/mL
- **DRUG:** Compound 31543 Calcitriol 80 μg/mL

## Key facts

- **NCT ID:** NCT01588522
- **Lead sponsor:** BPGbio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-17
- **Primary completion:** 2017-02-16
- **Final completion:** 2017-02-16
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588522, "Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01588522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*